Vuity

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

Novartis drops presbyopia drug acquired with Encore Vision

Novartis has abandoned development of its drug to treat presbyopia, a common age-related loss of near distance vision, after it failed a phase 2b trial. The eyedrop formulation of

News

AbbVie prices first presbyopia drug Vuity at $80 per month

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects.

Tenpoint eyes presbyopia drug launch after FDA nod

Novartis drops presbyopia drug acquired with Encore Vision

AbbVie prices first presbyopia drug Vuity at $80 per month

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Editor's Picks